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M olecular oxygen (O 2 ) and carbon dioxide (CO 2 ) are critical components of cardiovascular physiology (and pathophysiology). These gaseous molecules are central to tissue physiology and cellular respiration, and it has long been understood that disturbances in O 2 or CO 2 processing are both causative and indicative of pathophysiology. 1 Over time, however, it has become increasingly clear that nitric oxide (NO) is also an endogenous regulator in cardiovascular physiology and cellular respiration, operating at considerably lower concentrations than O 2 or CO 2 . These observations have led to the proposal that NO is the "third gas" of the respiratory cycle. [2] [3] [4] The major sources of NO in vivo are the NO synthase (NOS) isoforms. These include predominantly the neuronal (nNOS/NOS1), inducible (iNOS/NOS2) and endothelial (eNOS/NOS3) enzymes. It is worth noting that this naming system is primarily of historical significance; NOS tissue expression is far less strict than implied by this nomenclature, and all 3 isoforms may be constitutive or inducible. NOSs are heme-and flavin-containing enzymes that use NAPDH, tetrahydrobiopterin and O 2 to convert L-arginine to L-citrulline with concomitant release of NO. 5 
NO-Based Signaling: The Roles of cGMP and S-Nitrosylation
One of the earliest described intracellular receptors for NO is the soluble guanylyl cyclase (sGC). 6, 7 Binding of NO to the heme group of sGC leads to increased conversion of GTP to cGMP, which in turn activates protein kinase (PK)G. Despite the wealth of studies that have focused on sGC, it has become increasingly clear that NO exerts most of its cellular influence in a cGMP-independent manner. More generally, it is now appreciated that hemes in proteins do not generally mediate NO-based signaling that involves posttranslational protein modification, but rather serve to promote the requisite redox chemistry of NO. These observations led to the exploration of alternative molecular mechanisms through which NO might regulate cellular function, which culminated in the discovery of NO-mediated modification of protein cysteine residues (to generate an S-nitrosothiol [SNO]), designated S-nitrosylation ( Figure 1A ). 8, 9 Cysteine is a unique amino acid because of its thiol side chain. This functional group is nucleophilic, acidic (pK a Ϸ8) and redox active because of its hybridized p-and d-orbitals, which, together, underlie the large range of reactivities for cysteine residues within proteins. Within the realm of redox chemistry (ie, transfer of electrons and consequent change in atomic oxidation state), numerous reactions are known to occur on cysteine thiol side chains that affect protein structure and function. Of particular physiological significance is the redox reaction between NO and a cysteine thiol leading to S-nitrosylation (forming a protein SNO). In contrast to the and enzymatic protein denitrosylation mediated by the GSNOR and Trx systems (B). A, NOS synthesizes NO, which may activate sGC and thereby enhance production of cGMP (left) or subserve protein S-nitrosylation (right). The cGMPdependent pathway is deactivated by cGMP-phosphodiesterase, which hydrolyzes cGMP to GMP. (Phosphodiesterase may also be activated allosterically by cGMP.) The SNO-based mechanisms are dynamically regulated via S-nitrosylation and denitrosylation of a multitude of cysteine-containing proteins. In contrast to the multiple elements regulated by S-nitrosylation, the cGMP-based signaling system relies primarily on the cGMPdependent protein kinase, PKG. B, Proteins undergo reversible S-nitrosylation and denitrosylation (center). Denitrosylation mediated by GSNOR is depicted on the left. Transnitrosylation of glutathione (GSH) by S-nitrosylated proteins generates GSNO and native protein. GSNO undergoes NADH-dependent reduction by GSNOR to generate glutathione S-hydroxysulfenamide (GSNHOH), which can undergo further reaction with GSH to generate GSSG. The redox cycle is completed by reduction of GSSG to GSH via GSSG reductase. Denitrosylation mediated by the Trx system is depicted on the right. The active site dithiol motif (CXXC) of Trx1 (cytoplasmic) or Trx2 (mitochondrial) undergoes oxidation coupled to denitrosylation of SNO substrate. Oxidized Trx is reduced by the selenoprotein TrxR, which employs the reducing power of NADPH to regenerate active Trx.
Non-standard Abbreviations and Acronyms
cGMP axis that uses a single principal molecular effector (ie, PKG) to carry out the downstream functions of NO, S-nitrosylation allows for a wide range of NO-mediated functions, inasmuch as a plethora of proteins may undergo this modification. 8, 9 S-Nitrosylation therefore helps to explain the wide range of cellular effects of NO in the cardiovascular system, some of which are listed in Table 1. Table 2 provides dysregulated SNO proteins in cardiovascular disease.
In addition, the ongoing delineation of cellular SNO proteins has revealed multiple loci through which S-nitrosylation might influence levels of cGMP. It has been reported that S-nitrosylation inhibits sGC 10 and cGMP phosphodiesterase, 11 as well as eNOS itself 12 and eNOSregulating proteins including heat shock protein 90 13 and Akt/PKB. 14 PKG has regulatory thiols as well, which may be susceptible to S-nitrosylation. Furthermore, activating S-nitrosylation of arginase 15 and inhibitory S-nitrosylation of dimethylarginine dimethylaminohydrolase 16 would decrease NOS substrate levels and increase levels of endogenous, methylarginine NOS inhibitors, respectively.
Protein Denitrosylation: A Critical Regulator of SNO Biology
Numerous studies have focused on the mechanistic aspects of S-nitrosylation, leading to the identification of proteins that may either catalyze S-nitrosylation (eg, hemoglobin [Hb]), 17 or participate in protein transnitrosylation (ie, NO group transfer between proteins). 17, 18 More recently, however, protein denitrosylation has been shown to play a major role in controlling cellular S-nitrosylation 19 -21 (similar to the role of phosphatases in protein phosphorylation), and has been shown to operate on hundreds of proteins in intact cells. 21, 22 To date, 2 major enzymatic systems mediating denitrosylation have been described ( Figure 1B) , and are discussed in greater detail below. A number of enzymes have been reported to catalyze the reduction of SNOs, and thus may be viewed as candidate denitrosylases. One of the first described is known as S-nitrosoglutathione (GSNO) reductase (GSNOR). 23, 24 This enzyme uses the reducing power of NADH to convert GSNO to glutathione S-hydroxysulfenamide (GSNHOH), which in turn is converted to oxidized glutathione (GSSG); reduction of GSSG by glutathione reductase completes the denitrosylation cycle (GSSG reductase activity is therefore required for physiological denitrosylation of GSNO 25 ). Although GSNOR acts only on GSNO, ie, SNO proteins are not substrates, it governs protein S-nitrosylation by influencing the cellular equilibrium between SNO proteins and GSNO ( Figure  1B) . 26, 27 Importantly, GSNOR has been shown to play a role in regulating SNO signaling downstream of the ␤-adrenergic receptor (␤-AR) 28, 29 and is therefore operative in cellular signal transduction (discussed further below). Pharmacological inhibition or genetic deletion of GSNOR leads to enhanced vasodilation, 19, 30, 31 consistent with a role for GSNO in conveying the systemic activity of NO derived from eNOS.
GSNOR is an atypical member of the alcohol dehydrogenase family, inasmuch as it has no known alcohol-based substrate. In methylotrophic bacteria, GSNOR also metabolizes formalde- Examples of S-nitrosylated protein of interest and the general location and overall effect of S-nitrosylation. See Table 2 for dysregulated SNO-proteins in cardiovascular disease. MKP7 indicates mitogen-activated protein kinase phosphatase 7. Examples of proteins for which hypo-or hyper-S-nitrosylation has been implicated in the mechanism of disease. Note in addition that S-nitrosylation of multiple substrates including Cox2, Hif-1␣, the L-type Ca 2ϩ channel, RyR2 and SERCA2 is implicated in the cardio-protective effects of both statins and ischemia-or drug-induced preconditioning, and in amelioration of the effects of myocardial infarction (see text).
hyde. A recent report indicates that another NADPHoxidoreductase (carbonyl reductase 1) possesses GSNOR activity. 32 In addition, xanthine oxidase metabolizes GSNO, but the K m is high and its physiological relevance is therefore not clear. 33 Nonetheless, these studies, taken together, raise the idea that multiple enzymes may modulate GSNO levels in vivo.
A new line of investigation has recently revealed that the ubiquitous thioredoxin (Trx) enzyme family (originally described as protein disulfide reductases 34, 35 ) are also bona fide intracellular denitrosylases. 36, 37 In contrast to the strict substrate specificity of GSNOR for GSNO, a low-molecularweight SNO, the cytoplasmic and mitochondrial thioredoxins (Trx1 and Trx2, respectively) directly mediate the denitrosylation of multiple substrate SNO proteins. As illustrated in Figure 1B , the Trx system uses a Trx reductase (TrxR) and NADPH to regenerate reduced Trx following denitrosylation. Recent examples demonstrate that, in the context of signal transduction, denitrosylation by Trx/TrxR can be stimuluscoupled, substrate specific and spatially restricted (compartmentalized). 20, 21, 30 Accumulating evidence indicates that protein S-nitrosylation status in vivo is not determined simply by rates of NO synthesis (ie, NOS activities), but rather involves a precisely regulated equilibrium between S-nitrosylation and denitrosylation pathways, in particular involving transnitrosylation reactions between a variety of peptides and proteins, and that consequently protein denitrosylation is critical in SNO-based signal transduction. 8, 21 Enzymatic control of both S-nitrosylation and denitrosylation, established by stringent genetic criteria, underlies the spatiotemporal specificity necessary for cellular signaling. In addition, elucidation of the mechanisms of denitrosylation may provide novel genetic and pharmacological tools for manipulating SNO-based signaling in vivo (eg, as revealed in studies of GSNOR Ϫ/Ϫ mice; discussed further below) and help identify potential targets for therapeutic intervention in dysregulated SNO processing in the cardiovascular system. 38 
Roles of S-Nitrosylation in Vascular Signaling

Endothelium-Derived Relaxation Factor and Systemic Vascular Resistance
NO derived constitutively from eNOS (which mediates endothelium-dependent relaxation) is thought to account for the increase in blood pressure that is produced by both NOS inhibitors and genetic deletion of eNOS. It is worth considering in this light the implications of the findings that inhibitors of GSNOR elicit vasodilation 30 and deletion of GSNOR results in lowering of systemic vascular resistance 19, 31 ; GSNOR null mice are in fact highly susceptible to hypotension. 19 Thus, to the extent that peripheral vasodilation by eNOS is identified with endothelium-derived relaxation factor (EDRF), analysis in GSNOR mutant mice indicates that GSNO is a major effector of EDRF action.
Vasodilation by EDRF may be mediated by cGMP or may be cGMP-independent, depending on the animal species and vessel type. In the classic Furchgott bioassay of rabbit thoracic aorta, the EDRF response is equally dependent on cGMP-and non-cGMP-regulated pathways. 39, 40 Furthermore, increases in cGMP in and of themselves provide little insight into the nature of the NO-based effector, because both NO and GSNO can increase cGMP levels. In addition, cGMP elevations may either result not only from NO binding to heme in sGC but also from inhibitory S-nitrosylation of phosphodiesterase 5. 11 GSNO-based EDRF activity would be fully consistent with these data. GSNO is in equilibrium with protein SNO, and it has recently been reported that shearinduced activation of endothelial cells is associated with S-nitrosylation of more than 100 proteins. 41 Furchgott's EDRF was not generated by shear but rather by acetylcholine, a G protein-coupled receptor (GPCR) agonist that both activates eNOS and releases NO from SNO-protein reservoirs. 172 As discussed in more detail below, it has been shown recently that GPCR-mediated vasodilation via a different, eNOS-coupled GPCR, the ␤ 2 -AR, is regulated critically by and very likely dependent in large part on GSNO-mediated S-nitrosylation of a set of proteins that includes G protein-coupled receptor kinase GPCR kinase (GRK)2. 28, 29, 42 Inhibition of GRK2 by S-nitrosylation prevents receptor densensitization. Thus, the available evidence is consistent with a prominent role for SNO in conveying NO-based vasodilatory signals. [43] [44] [45] Substantial evidence supports a model in which endothelial dysfunction contributes to evolution of vascular disease, including hypertension, diabetes and atherosclerosis. A signature feature of this model is the excess production of superoxide, which eliminates NO. 43 Endothelial sources of superoxide include NADPH oxidases and eNOS itself, through a process known as "uncoupling" that results from cofactor or substrate deficiency. It is therefore of interest that S-nitrosylation of NADPH oxidase may preserve NO bioavailability in healthy endothelium by inhibiting production of superoxide. 44 By contrast, excessive S-nitrosylation of arginase has been implicated in the uncoupling eNOS that is characteristic of arteriosclerotic vessels. 45 It has been recently suggested that impaired S-nitrosylation of endothelial clock-related proteins may be linked to hypertension, 46 emphasizing the emerging theme that hypo-and hyper-nitrosylation of specific protein targets, rather than a general NO/superoxide imbalance that may be interpreted principally in terms of altered levels of NO, may correlate best with pathophysiology.
Angiogenesis
Endogenously synthesized NO is an established facilitator of endothelial function and survival: eNOS is both induced and activated following endothelial stimulation with vascular endothelial growth factor (VEGF), 47, 48 a major promoter of vessel growth in vivo, as well as by shear stress. 49 Importantly, eNOS Ϫ/Ϫ mice are deficient in VEGF responsiveness, thus establishing that NO is indeed a critical element in angiogenesis. 50 It has also been demonstrated that both shear stress 41, 51 and VEGF 52, 53 regulate protein S-nitrosylation in the vascular endothelium. In a recent specific example, VEGF production downstream of the chemokine-type GPCR CXCR4 was shown to be intimately coupled to S-nitrosylation of MKP7 (mitogen-activated protein kinase phosphatase 7), which facilitates endothelial cell migration via activation of JNK3 (c-Jun N-terminal kinase 3), thus promoting angiogenesis. 54 Promotion of endothelial cell survival and angiogenesis also appears to be mediated via S-nitrosylation and activation of dynamin, 55 a regulator of endothelial cell endocytosis. Finally, endothelial S-nitrosylation is perturbed by known pathophysiological stimuli including aging 56 and hyperglycemic states, 57 clearly linking defective S-nitrosylation to vascular disease.
It is well recognized that hypoxia stimulates angiogenesis primarily via the transcription factor hypoxia-inducible factor (HIF), which augments VEGF expression. 58 Under normoxic conditions, HIF is typically undetectable because of rapid proteolytic degradation that is initiated by prolyl hydroxylation. Interestingly, exogenously administered SNO donors exert a hypoxia-mimetic effect, 59 ,60 leading to nuclear accumulation of HIF. HIF stabilization by SNO under conditions of normoxia, observed both in vitro 61, 62 and in vivo, 31 is mediated by S-nitrosylation of HIF itself. Specifically, HIF is constitutively S-nitrosylated in normoxic GSNOR Ϫ/Ϫ mice, with increased binding of S-nitrosylated HIF to the gene for VEGF. 31 These mice also exhibited increased myocardial capillary density, lending further support for an integral role of S-nitrosylation in promoting angiogenesis.
Apoptosis
Some of the earliest studies examining the functions of S-nitrosylation focused on the antiapoptotic/protective effects of endogenous NO. 63 These efforts demonstrated that NO S-nitrosylates and inhibits the active site cysteine residue of the proapoptotic effector caspase-3. 64 -66 It was shown subsequently that caspase-3 undergoes stimulus-coupled activation, driven by proapoptotic Fas stimulation, via Trxmediated denitrosylation. 20 Importantly, this mechanism has been shown to operate in endothelial cells, 67 suggesting that the S-nitrosylation/denitrosylation equilibrium of caspase-3 may be a critical determinant of endothelial cell survival and vessel function. Furthermore, the oxidoreductase function of Trx, a vital element in preserving endothelial redox equilibrium and protecting against the deleterious effects of oxidative and/or nitrosative stress, is itself stimulated by S-nitrosylation. 68 
Inflammation
The robust antiinflammatory attributes of NO were first appreciated in experimental observations of diminished leukocyte adherence to vascular endothelium in the presence of exogenous NO donors. 69 Administration of NOS inhibitors predictably results in increased leukocyte rolling along the endothelium. Studies in knockout mice lacking a specific NOS isoform also underscore the contribution of endogenous NO sources in mitigating leukocyte adherence: compared to wild-type, eNOS Ϫ/Ϫ , nNOS Ϫ/Ϫ , and iNOS Ϫ/Ϫ mice exhibit increased leukocyte adherence to endothelium. 70, 71 The molecular bases of these findings have been elucidated in part, and encompass 2 key areas of SNO-mediated regulation: control of endothelial protein trafficking and suppression of nuclear factor B-dependent expression of proinflammatory cytokines and adhesion molecules. 72 During the initial phase of an inflammatory response, leukocyte rolling requires interactions between P-selectins on the endothelial cell surface with the cognate P-selectin glycoprotein ligand-1 on the leukocyte surface. P-Selectins are transmembrane proteins that reside within resting endothelial cells in granules designated Weibel-Palade bodies. On endothelial cell activation by an inflammatory stimulus, these granules translocate to the cell surface, resulting in exposure of P-selectin to the vessel lumen. N-Ethylmaleimide-sensitive factor (NSF), a principal component of this exocytic trafficking machinery, is subject to direct inhibition by S-nitrosylation of critical cysteine residues. 73 The resultant interruption of NSFmediated disassembly of soluble NSF-attachment protein receptor (SNARE) complexes prevents Weibel-Palade body exocytosis from endothelial cells. Thus, S-nitrosylation of NSF, consequent, for example, on stimulation with the GPCR agonist thrombin, is identified with the antiinflammatory activity of eNOS (Figure 2) . Similarly, inhibitory S-nitrosylation of NSF in platelets is antithrombotic through a similar mechanism (see below). 74 Other phases of the inflammatory response and leukocyte trafficking are impacted by S-nitrosylation. Specifically, NO has been shown to limit the expression of integrins and intracellular adhesion molecules required for leukocyte adherence. [75] [76] [77] These and other proinflammatory effectors, including cytokines and cytokine receptors, are under direct transcriptional control by nuclear factor B. 78 Inhibitory S-nitrosylation of both nuclear factor B 79 and its upstream activating enzyme complex, inhibitory B kinase, 80 has been demonstrated in multiple studies. Taken together, these demonstrations of multiple loci of S-nitrosylation in the inflammatory signaling cascade support a comprehensive and multifaceted regulatory scheme akin to that subserved by phosphorylation/dephosphorylation. It may be anticipated that the antiinflammatory actions of NO via S-nitrosylation will be relevant across a range of vascular pathologies from atherosclerosis to vasculitis and septic shock. Figure 2 . S-Nitrosylation of NSF is antiinflammatory and antithrombotic. 73, 74 In endothelial cells, inhibitory S-nitrosylation of NSF suppresses exocytosis of Weibel-Palade bodies and thereby externalization of P-selectin, which inhibits leukocyte rolling and thus vascular inflammation. Similarly, in platelets (labeling in parentheses), inhibitory S-nitrosylation of NSF suppresses exocytosis of secretory granules and thereby externalization of P-selectin (and other adhesive molecules), which reduce platelet activation, adhesion, aggregation, and rolling on the endothelium. These effects are antithrombotic.
Fusion/ Exocytosis
Reperfusion Injury
Following a period of transient tissue ischemia, reestablishment of vascular blood flow and O 2 delivery causes paradoxical tissue damage referred to as "reperfusion injury". 81 Elucidating the biochemical and molecular mechanisms of reperfusion injury has been an active area of investigation, inasmuch as amelioration would be of significant benefit during both percutaneous and pharmacological reperfusion techniques. Altered S-nitrosylation is intimately linked with reperfusion injury, helping to explain the salutary actions of statins, estrogen, and mitochondrial respiratory chain inhibitors. In particular, atorvastatin stimulates iNOS-mediated S-nitrosylation of cyclooxygenase 2, 82 thereby generating cytoprotective prostaglandins. In addition, estrogen appears to exert its cardioprotective effect, at least in part, by augmenting S-nitrosylation of mitochondrial proteins. [83] [84] [85] Whereas dysregulated S-nitrosylation appears to facilitate injury via irreversible inhibition of mitochondrial complex I (necessary for converting electrons from NADH to an ATPproducing proton gradient), 86 -88 targeted delivery of nitrosylating agents to mitochondria is protective in ischemia/ reperfusion (I/R), and inhibition of reactive oxygen generation by complex I may be involved. 89 iNOS also contributes to the protective effects of preconditioning (exposure to moderate hypoxia before I/R, which attenuates reperfusion injury) that are partly recapitulated by nitroglycerin. 90, 91 Inasmuch as nitroglycerin bioactivation occurs predominantly in mitochondria and results in accumulation of protein S-nitrosothiols, 92 it may be suggested that S-nitrosylation plays a protective role. 85, 89, 93, 94 In support of this idea, SNO proteins that have been shown to increase in preconditioned hearts are also identified following I/R. 95 
Atherogenesis, Risk Factors, and Circulating SNO
Defective S-nitrosylation may contribute significantly to the pathophysiology of atherosclerosis. This condition reflects a contribution from myriad factors, including disruptions in the NO/redox equilibrium, immunologic/inflammatory stresses, platelet activation, aberrant vessel tone, and age-associated endothelial dysfunction. A major role in atherosclerosis for oxidative stress with resultant NO/redox disequilibrium is well characterized. 43 As described above, Trx functions as a critical regulator of cellular redox status and as an important modulator of S-nitrosylation. Recent studies suggest that statins, frequently used antidyslipidemic and vasculoprotective agents, may exert their effects, at least in part, by inducing both S-nitrosylation and activation of Trx. 96 Platelet activation is highly relevant in atherosclerosis. The role of NO in platelet biology has been complicated in recent years by findings that both eNOS and iNOS may contribute to platelet cGMP production, and that cGMP may exert both inhibitory and stimulatory effects. 97 In addition, accumulating evidence also supports the idea that NO may inhibit platelet aggregation via a cGMP-independent pathway. 98 -102 Platelet aggregation is the third and final stage of the platelet activation process, preceded by platelet adherence and granule secretion (exocytosis). The contents of the various platelet granules (ie, dense, ␣-, and lysosomal granules) figure prominently in platelet recruitment, rolling, adherence, and aggregation. As in the case of endothelial exocytosis discussed above, S-nitrosylation of NSF also exerts an inhibitory effect on exocytosis in platelets, thereby suppressing thrombosis and vascular inflammation (Figure 2 ). 74 These effects are mediated by endogenously generated NO, inasmuch as platelets from eNOS Ϫ/Ϫ mice exhibit increased rolling on venules, increased arteriolar thrombosis, and increased exocytosis in vivo. 74 Hypertension is a primary risk factor for progression of atherosclerotic disease and cardiovascular morbidity and mortality. Endogenous SNOs are implicated as key mediators of vasodilation and blood pressure control, 19, 46, 103 and in plasma, SNO-albumin provides a major reservoir of NO bioactivity. 104 However, albumin can also serve as a deleterious NO sink, whereby excessive sequestration of endogenous NO as S-nitrosoalbumin (SNO-albumin) negatively impacts vascular homeostasis in a variety of pathophysiological states. 103 Notably, albumin infusions may precipitate elevations in blood pressure by limiting the pool of bioavailable SNO for basal vessel relaxation. 105 Similarly, increased plasma SNO levels, suggestive of impaired NO delivery or excessive NO sequestration, are associated with adverse cardiovascular outcomes and hypertension in end-stage renal disease patients, 106 and misappropriation of NO as SNO-albumin is also directly implicated in the pathogenesis of hypertension in preeclampsia. 107, 108 It is important to emphasize, however, that exogenously administered SNO-albumin has been shown to serve as an effective therapeutic agent in a number of animal models including I/R-associated heart damage, 109, 110 lung injury in sickle cell disease 111 and cardiopulmonary dysfunction in endotoxemia. 112, 113 A number of studies have confirmed that the aging process is accompanied by a progressive decrease in bioavailable NO and concomitant endothelial dysfunction. 15,114 -116 Explanations include increased superoxide production and elevated levels of naturally occurring NOS inhibitors. Upregulation of arginase activity in aging vasculature has also been espoused as a predominant mechanism for age-related endothelial dysfunction. Elevated levels of arginase, which competes directly with NOS for the common substrate L-arginine, would theoretically limit the amount of NO synthesized. Indeed, it was reported that in vitro inhibition of arginase activity restores (NO-based) vasodilation in aortic rings derived from aged rats. 114, 116 A subsequent study revealed that arginase is activated by S-nitrosylation of a single cysteine residue, leading to its stabilization and to substantially enhanced substrate affinity (6-fold reduction in K m ), 15 which might enhance its ability to compete with NOS. Moreover, S-nitrosylation of arginase was increased in blood vessels from aging rats and was mediated by iNOS, previously shown to be expressed in aging vasculature. 115 
SNO-Hb and Hypoxic Vasodilation
Hypoxic vasodilation is an autoregulatory physiological response that maximizes blood flow to regions in the arterial periphery with low Hb O 2 saturation, thereby matching perfusion with tissue O 2 demand. 4, 17, 117 The progressive diminution in blood O 2 content accompanying the decline in arteriolar diameter within the microcirculation results in graded vasodilation. Autoregulation of blood flow occurs within seconds or less (A-V transit times) and is recapitulated by direct intra-arterial infusion of variably deoxygenated but not of oxygenated RBCs, 118 and RBCs added to aortic ring bioassays at varying PO 2 actuate graded vasodilation ( Figure  3A) . 17 Moreover, these RBC-induced responses can be replicated by S-nitrosohemoglobin (SNO-Hb), which has a well-documented role in mediating hypoxic vasodilation. 4,119 -122 Infusion of SNO-Hb (but not unmodified Hb) augments blood flow in vivo under normoxic conditions ( Figure 3B ), 122 and vasodilation is blunted in the setting of supraphysiologic PO 2 (eg, ambient O 2 at 3 atmospheres absolute) ( Figure 3C ). 122 By contrast, hypoxemia augments vasodilation by SNO-Hb. Changes in peripheral blood flow and PO 2 are predictably correlated with circulating SNO-Hb concentrations. 123 Hb exists predominantly in one of 2 structural states: R (relaxed) (high O 2 affinity) and T (tense) (low O 2 affinity). 120 S-Nitrosylation of Hb (to generate SNO-Hb) occurs at Cys93 of the ␤ subunit (Cys ␤93). 120 The allosteric conformation of the Hb molecule governs reactivity of the Cys ␤93 residue and thus the propensity for NO binding ( Figure 3D ). SNO-Hb formation is favored in the oxygenated (R) structure, whereas in the T configuration (eg, hypoxia, low pH), NO groups are released to the surrounding tissues with resultant vasodilation. The duality of SNO-Hb as simultaneous O 2 carrier and NO donor may plausibly be harnessed in creating viable blood substitutes, with some applicability already reported in ischemic myocardium. 124 Additionally, it appears that the coronary vasodilator nitroglycerin improves perfusion of ischemic myocardium by utilizing SNO-Hb-mediated O 2 delivery in concert with NO unloading. 125 Inasmuch as RBCs play a central role in autoregulation of blood flow, 4 perturbations in the delivery of SNO by RBCs may underlie a variety of pathophysiological states characterized by microvascular dysfunction. 126 For example, pulmonary hypertension, a clinical entity often triggered by sustained hypoxemia, leads to depletion of RBC SNO-Hb stores and consequently to defective PO 2 -coupled vasoregulation and ventilation/perfusion mismatching. 127 Moreover, in vivo repletion of SNO-Hb can correct these physiological deficits. Defective production of SNO-Hb by sickle RBCs has been implicated in impaired vasoregulation in sickle cell disease; the severity of symptoms is correlated with the degree of impairment of SNO-Hb processing and of RBC-mediated vasodilation, and these deficits can be ameliorated by repletion of SNO-Hb. 128 In diabetes, derangements of SNO delivery by RBCs, resulting from glycosylation of Hb, which promotes the R configuration and thereby limits NO delivery, may exacerbate the vasculopathy associated with this disease. 129, 130 
Roles of S-Nitrosylation in Cardiac Signaling
Electrophysiology
Within the heart, S-nitrosylation has emerged as a ubiquitous signaling modality, impacting virtually every facet of cardiac function and dysfunction. The elaborate cascade of Ca 2ϩ cycling that underlies excitation-contraction coupling (ECC) is no exception. 131 ECC spans an ordered sequence from electric excitation of the individual myocyte to heart contraction, subserved by the tightly regulated trafficking of Ca 2ϩ flux from one cellular compartment to another. 132 On membrane depolarization of the cardiac myocyte generated by voltage-gated Na ϩ channels, a cytosolic influx of Ca 2ϩ occurs via the plasmalemmal L-type Ca 2ϩ channel. Through a process known as Ca 2ϩ -induced Ca 2ϩ release, this initial Ca 2ϩ current triggers a more pronounced Ca 2ϩ release from the sarcoplasmic reticulum (SR) through the ryanodine receptor (RyR)/Ca 2ϩ release channel (RyR2). Myocyte contraction proceeds when Ca 2ϩ binds to troponin C in myofilaments, activating myosin ATPase. Relaxation of the myocyte entails diastolic reuptake and extrusion of cytosolic Ca 2ϩ by way of the SR Ca 2ϩ ATPase (SERCA2a) and the sarcolemmal Na ϩ /Ca 2ϩ exchanger, 132 respectively. The ion channels participating in ECC, as well as those that determine the shape and duration of the action potential (see below), are modulated by S-nitrosylation, 85, 131, [133] [134] [135] [136] [137] [138] which thereby exerts effects on both contractility and arrhythmogenesis. The specific effects exerted by NO in the myocyte are dictated in part by the subcellular compartmentalization of NOSs (NOS1and NOS3), which reside in close proximity to substrates for S-nitrosylation (Figure 4) . 139 NOS3 is spatially confined to sarcolemmal membrane caveolae and is thus adjacent to the L-type Ca 2ϩ channel, whose S-nitrosylation inhibits ion influx. 135, 140 In a similar fashion, NOS1 resides in the SR where it is complexed with RyR2, and S-nitrosylation activates RyR2 (increases channel opening probability [P o ]). 136, 141 Colocalization and targeted S-nitrosylation may also hold true for SERCA2a. 142, 143 Collectively, these observations demonstrate the precise spatiotemporal regulation of S-nitrosylation that underlies control by NO of cardiac ECC.
It has been reported that nNOS redistributes to the sarcolemma in heart failure, where it may regulate both ␤-adrenergic responsiveness and Ca 2ϩ flux, [143] [144] [145] and the deleterious consequences of myocardial infarction in mice (ventricular arrhythmia and mortality) are significantly more severe in nNOS Ϫ/Ϫ animals than in wild-type animals, in association with decreased S-nitrosylation of L-type Ca 2ϩ channels. 143 Thus, inhibitory S-nitrosylation of L-type Ca 2ϩ channels by nNOS is likely antiarrhythmogenic.
More generally, disruption of the NO/redox equilibrium in myocytes, through alteration of either levels or spatiotemporal distribution of NO/reactive oxygen species, is widely regarded as a sine qua non of heart failure. 146 Upregulation of oxidant production, notably by xanthine oxidase, can overwhelm endogenous, NO-based signaling and promote the mechanoenergetic uncoupling characteristic of cardiac dysfunction. 147 Therapies directed against xanthine oxidase enable reverse remodeling in rats with dilated cardiomyopathy. 148 Thus, restoration of NO/redox homeostasis provides a potentially fruitful approach to restoring cardiac contractile function. 149 Figure 4 . S-Nitrosylation regulates myocardial Ca 2ϩ handling and thereby ECC. RyR2, the cardiac form of the tetrameric ryanodine receptor/Ca 2ϩ release channel, is localized to the SR membrane in proximity with the plasma membrane L-type calcium channel, which provides the substrate for calciummediated calcium release from SR to cytosol. The SR-localized Ca 2ϩ -ATPase (SERCA) replenishes SR Ca 2ϩ . RyR2 colocalizes with nNOS in the SR, and S-nitrosylation of RyR2 (mediated by GSNO) potentiates Ca 2ϩ release. As in skeletal muscle RyR1, physiological S-nitrosylation of one or a few cysteines within each RyR2 monomer is likely to be the case. S-Nitrosylation of the L-type calcium channel (␣ 1C subunit; resulting in, for example, attenuated ␤-AR-dependent contractility) and of SERCA is inhibitory. Hypo-S-nitrosylation of RyR2 is associated with diastolic Ca 2ϩ leakage and arrhythmia characteristic of sudden cardiac death. S-Nitrosylation of the L-type calcium channel has been associated with ischemic preconditioning that reduces reperfusion injury, whereas hyper-S-nitrosylation of the L-type calcium channel has been associated with atrial fibrillation. Note, in addition, that aberrant S-nitrosylation can result from the translocation of nNOS to the plasma membrane that is seen in association with myocardial infarction and cardiomyopathy. Furthermore, aberrant and in particular hyper-S-nitrosylation can result in irreversible oxidative modification of S-nitrosylated proteins in concert with reactive oxygen species produced by endogenous enzymes including xanthine oxidase. Figure 5 . Schematic summary of the regulation of agonist-induced ␤ 2 -AR trafficking by S-nitrosylation/denitrosylation of ␤-arrestin 2 (␤-Arr2), GRK2, and dynamin. A, ␤-Arrestin 2 serves as a scaffold that functionally colocalizes eNOS and ␤-ARs (as well as other GPCRs). Ligand (isoproterenol) stimulation results in activation of eNOS and S-nitrosylation of ␤-arrestin 2. S-Nitrosylation of ␤-arrestin 2 promotes its dissociation from eNOS and its association with clathrin heavy chain/␤-adaptin (AP-2), which facilitates routing of the ␤ 2 -AR into the clathrin-based endocytotic pathway, and ␤-arrestin 2 is subsequently denitrosylated. B, Inhibition of GRK2 by ligandcoupled S-nitrosylation suppresses agonist-stimulated ␤-AR phosphorylation, ␤-arrestin 2 recruitment, and receptor desensitization and downregulation (schematic at top). Bottom, Desensitization (decline in cardiac contractility in the continued presence of ISO) is enhanced by inhibiting NO production. C, After GPCR activation, eNOS-mediated S-nitrosylation of dynamin promotes multimerization and GTPase activity, as well as relocation to the plasma membrane, which facilitates scission of endocytotic vesicles and receptor internalization. Adapted from Ozawa et al 28 and Whalen 29 et al.
␤-AR System
In cardiac myocytes, eNOS is activated following ␤-AR stimulation, 150 and important roles have been demonstrated for S-nitrosylation in transducing adrenergic signals. For example, S-nitrosylation of the L-type Ca 2ϩ channel increases following isoproterenol stimulation in an eNOSdependent manner. 135 Interestingly, a difference in protein S-nitrosylation appears to explain, at least in part, the gender disparity in I/R injury: females exhibit higher SNO levels and improved protection. 83 Densensitization of GPCRs is a characteristic feature of disease, as is a deficiency of NO bioactivity. Recent studies have helped to connect these phenomena by demonstrating that GRK2 undergoes agonist-coupled, inhibitory S-nitrosylation ( Figure 5B ). GRK2 activity is a molecular correlate of receptor densensitization. Thus, S-nitrosylation leads to decreased ␤-AR phosphorylation and desensitization, 29 and absent S-nitrosylation, cardiac contractility declines rapidly during maintained adrenergic stimulation ( Figure 5B ). ␤-Arrestin 2, a scaffolding protein that targets receptors for stimulus-coupled internalization, has also been shown to undergo S-nitrosylation, 28 leading to enhanced eNOS-dependent receptor trafficking ( Figure  5A ). Importantly, these studies reported increased protein S-nitrosylation (SNO-GRK2 and SNO-␤-arrestin) in GSNOR Ϫ/Ϫ mice. Finally, S-nitrosylation of dynamin facilitates clathrin-dependent endocytosis of membrane receptors including the ␤-AR and thereby receptor downregulation ( Figure 5C ). 151 S-Nitrosylation is thus under enzymatic control and GSNO is a central player in ␤-AR signaling. Other studies have demonstrated that VEGF may regulate GSNOR expression 152 ; crosstalk between VEGF (and other provascular signals) and ␤-ARs may be mediated via the GSNOR/S-nitrosylation axis.
Arrhythmogenesis
As indicated above, the shape and duration of the cardiac action potential are regulated by multiple ion channels that are subject to regulatory S-nitrosylation. 138 ( Figure 6 summarizes findings in the case of the ventricular action potential.) For example, the inward-rectifying K current (IK 1 ) shapes phase 3, and S-nitrosylation of a single cysteine in the relevant channel protein, Kir2.1, shortens the action potential. 153 Chronic atrial fibrillation was associated with decreased Kir2.1 S-nitrosylation, as assessed in human atrial samples.
A role for dysregulated S-nitrosylation in the development of a number of cardiac arrhythmias is supported by additional studies. Gonzalez et al 141 demonstrated that nNOS-mediated S-nitrosylation of RyR2 is critical for maintaining intracellular Ca 2ϩ homeostasis (Figure 4 ). Mice deficient in nNOS exhibit a diastolic calcium leak, 141 which creates contractile dysfunction and a proarrhythmogenic state. 154, 155 nNOS mutant mice also exhibit a proarrhythmic state following myocardial infarction, which is associated with diminished S-nitrosylation of RyR2, SERCA2a, and L-type calcium channel. 143 Mutations in ␣-syntrophin, a dystrophin-associated protein that acts as a scaffold between nNOS and the plasma membrane Ca-ATPase, 156 have been shown to contribute to a long-QT syndrome. 157 The Ala3903 Val mutation in ␣-syntrophin alters the inhibitory interaction between nNOS and the plasma membrane Ca-ATPase, and the resultant S-nitrosylation of the Na ϩ channel SCN5A enhances Na ϩ influx, 157 a proarrhythmic event recapitulating long-QT syndrome.
Conclusions
NO plays an important role in virtually all aspects of cardiac and vascular physiology. However, the molecular details are understood in only very few instances. The emergence of SNOs as second messengers and of S-nitrosylation as the preeminent NO-based signal presages a new era in cardiovascular biology. Unraveling the molecular underpinnings of SNO-based cardiovascular function and pathophysiology will undoubtedly yield novel therapeutic targets with great potential to improve clinical outcomes. 38 
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